1. Stem-Cell-like Properties and Epithelial Plasticity Arise as Stable Traits after Transient Twist1 Activation
   Johanna M. Schmidt et al, 2015, Cell Reports CrossRef
2. Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report
   HIROKO WATANABE et al, 2015 CrossRef
3. Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer
   Marina Cardó-Vila et al, 2016, The American Journal of Pathology CrossRef
4. Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance
   Harun Patel et al, 2017, European Journal of Medicinal Chemistry CrossRef
5. Upregulation of MUC1 by its novel activator 14-3-3ζ promotes tumor invasion and indicates poor prognosis in lung adenocarcinoma
   Min Xue et al, 2017 CrossRef
6. Approved and Clinical Trial Third-Generation EGFR Inhibitors
   Harun M. Patel et al, 2019 CrossRef
7. Lung Cancer Stem Cells
   Gavitt A. Woodard et al, 2015 CrossRef
8. Genomically Driven Precision Medicine to Improve Outcomes in Anaplastic Thyroid Cancer
   Nicole Pinto et al, 2014, Journal of Oncology CrossRef
9. Synthetic approaches to protein phosphorylation
   Zan Chen et al, 2015, Current Opinion in Chemical Biology CrossRef
10. What are the options for non-small-cell lung cancer patients post second-line therapy?
    Diego Luigi Cortinovis et al, 2015, Future Oncology CrossRef
11. New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer
    Laird Cameron et al, 2015, Curr. Treat. Options in Oncol. CrossRef
12. Novel targeted agents for the treatment of lung cancer in China
    Si-Yang Liu et al, 2015, Cancer CrossRef
13. Risk of Hypertension With Sorafenib Use in Patients With Cancer
    XiongWen Yang et al, 2017, American Journal of Therapeutics CrossRef
14. Agents in the preclinical development stage for non-small cell lung cancer
    Paola Claudia Sacco et al, 2015, Expert Review of Anticancer Therapy CrossRef
15. Prognostic impact and potential interaction of EGFR and c-Met in the progression of esophageal squamous cell carcinoma
    Haixing Wang et al, 2016, Tumor Biol. CrossRef
16. ALKgene alterations in cancer: biological aspects and therapeutic implications
    Raffaele Palmirotta et al, 2017, Pharmacogenomics CrossRef
17. Crizotinib
    Giuseppe Tridente, 2017 CrossRef
18. Kinases
    Giuseppe Tridente, 2017 CrossRef
19. A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer
    Saphy Sharda et al, 2019, CTMC CrossRef
20. Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies
    Bo Li et al, 2019, International Journal of Analytical Chemistry CrossRef
21. Significance of a Liquid Biopsy on Lung Cancer
    Naoko Aragane, 2020, JJLC CrossRef
22. Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas
    Hui Li et al, 2016, Oncotarget CrossRef
23. Effects of miR‑340 overexpression and knockdown on the proliferation and metastasis of NSCLC cell lines
    Xidan Zhu et al, 2019, Int J Mol Med CrossRef
24. Current achievements and future perspectives with liquid biopsy
    Naoko Sueoka-Aragane, 2020, Pers Med Univers CrossRef
25. The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer
    Tania Crombet Ramos et al, 2021, Front. Oncol. CrossRef
26. Detection of Novel Fusion Transcript VTI1A-CFAP46 in Hepatocellular Carcinoma
    Shunichi Tsuge et al, 2019, Gastrointest Tumors CrossRef
27. Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment
    Peng Gao et al, 2022, Front. Oncol. CrossRef
28. Long-term disease control in a patient with ALK-positive non-small cell lung cancer
    G. I. Berezina et al, 2022, Medicinskij sovet CrossRef
29. Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data
    Gouji Toyokawa et al, 2015, Oncol Res Treat CrossRef
30. Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma
    Chunxiao Liu et al, 2024, Nat Commun CrossRef